8-K: Catheter Precision Implements 1-for-10 Reverse Stock Split and Reduces Authorized Shares

Catheter Precision has enacted a 1-for-10 reverse stock split and reduced its authorized common stock from 300 million to 30 million shares, effective July 15, 2024.

Summary

• Catheter Precision's board of directors approved a 1-for-10 reverse stock split of its common stock.
• The company's authorized common stock was reduced from 300 million shares to 30 million shares.
• The reverse stock split and authorized share reduction will be effective on July 15, 2024, at 12:01 a.m. Eastern Time.
• The common stock will begin trading on a split-adjusted basis on the NYSE American on July 15, 2024.
• The reverse stock split will reduce the number of outstanding shares from approximately 9,012,518 to approximately 901,251.
• Fractional shares resulting from the split will be aggregated and sold, with proceeds distributed to shareholders.
• The reverse stock split will not change any stockholder's percentage ownership or voting power, except for minor changes due to fractional shares.
• Adjustments will be made to stock options, warrants, and preferred stock conversion prices to reflect the reverse split.

Sentiment

Score: 5

Explanation: The document describes a reverse stock split and reduction in authorized shares, which are generally neutral to slightly negative events. While the company is taking steps to manage the impact, the action itself is not inherently positive.

Positives

• The reverse stock split will not change any stockholder's percentage ownership or voting power, except for minor changes due to fractional shares.
• The company has taken steps to ensure fractional shares are handled fairly by aggregating and selling them, with proceeds distributed to shareholders.

Negatives

• The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
• The reduction in authorized shares could limit the company's flexibility for future capital raises.

Risks

• Reverse stock splits are often viewed negatively by the market and can lead to a decrease in share price.
• The reduction in authorized shares could limit the company's ability to raise capital in the future.
• The company's stock price may be volatile following the reverse split.

Future Outlook

The company will continue to operate with the reduced number of outstanding shares and authorized shares. The company will also need to manage the impact of the reverse stock split on its stock price and investor perception.

Management Comments

• The Board determined to effect a reverse split of the Common Stock at a ratio of 1-for-10.
• The Board has the authority, at its discretion, to file a certificate of amendment to the Companys restated certificate of incorporation to effect a reverse split of the Companys issued common stock.

Industry Context

Reverse stock splits are often used by companies to increase their stock price and avoid delisting from exchanges. This action is not uncommon in the biotech and medical device industry, especially for companies with low share prices.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies facing low share prices, particularly in the biotech sector where companies often have high research and development costs and may not be profitable.
• Other companies that have recently performed reverse stock splits include Xometry, Inc. (XMTR) and Faraday Future Intelligent Electric Inc. (FFIE).
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can range from 1-for-2 to 1-for-25 or more.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same, except for minor changes due to fractional shares.
• Employees with stock options or warrants will see adjustments to their holdings.
• The company's stock price may be volatile following the reverse split, impacting all stakeholders.

Next Steps

• The company's common stock will begin trading on a split-adjusted basis on July 15, 2024.
• Stockholders will receive proceeds from the sale of aggregated fractional shares.
• The company will need to manage the impact of the reverse stock split on its stock price and investor perception.

Key Dates

Keywords

reverse stock split, authorized shares, common stock, stock split, share reduction, VTAK, NYSE American, corporate action